New York State Teachers Retirement System Has $48.69 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

New York State Teachers Retirement System lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 86,587 shares of the biopharmaceutical company’s stock after selling 992 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Regeneron Pharmaceuticals worth $48,685,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MASTERINVEST Kapitalanlage GmbH boosted its position in shares of Regeneron Pharmaceuticals by 46.5% during the third quarter. MASTERINVEST Kapitalanlage GmbH now owns 3,176 shares of the biopharmaceutical company’s stock valued at $1,786,000 after buying an additional 1,008 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its position in Regeneron Pharmaceuticals by 7.2% in the 3rd quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 1,697 shares of the biopharmaceutical company’s stock valued at $954,000 after buying an additional 114 shares during the last quarter. Kesler Norman & Wride LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $249,000. Oregon Public Employees Retirement Fund boosted its holdings in Regeneron Pharmaceuticals by 30.6% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 11,667 shares of the biopharmaceutical company’s stock worth $6,560,000 after acquiring an additional 2,736 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its holdings in Regeneron Pharmaceuticals by 238.6% during the 3rd quarter. Cromwell Holdings LLC now owns 342 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 241 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,431 shares of company stock valued at $5,733,521 over the last three months. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Regeneron Pharmaceuticals Trading Down 0.6%

NASDAQ:REGN opened at $796.55 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $738.12 and its 200 day moving average is $629.56. The stock has a market capitalization of $83.72 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 2.16 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period last year, the business posted $12.46 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their target price for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Wells Fargo & Company lifted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Citigroup upped their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Royal Bank Of Canada lifted their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $791.05.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.